(Q39217647)

10 September 2017

Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. (English)

1 reference

10 September 2017

1 reference

3

Peter Hillmen

0 references

Susan O'Brien

4

object named as

Susan O'Brien

1 reference

10 September 2017

13

Claire Dearden

1 reference

10 September 2017

22

John C Byrd

1 reference

10 September 2017

14

Tadeusz Robak

1 reference

10 September 2017

17

Jan A Burger

1 reference

10 September 2017

21

Danelle F James

1 reference

10 September 2017

1

Paul M Barr

1 reference

10 September 2017

8

Stephen P Mulligan

1 reference

10 September 2017

9

Ulrich Jaeger

1 reference

10 September 2017

11

Florence Cymbalista

1 reference

10 September 2017

12

Marco Montillo

1 reference

10 September 2017

7

Steven Coutre

1 reference

10 September 2017

Juthamas Sukbuntherng

19

object named as

Juthamas Sukbuntherng

1 reference

10 September 2017

Jacqueline Barrientos

5

object named as

Jacqueline C Barrientos

1 reference

10 September 2017

Jennifer R Brown

2

1 reference

10 September 2017

Nishitha M Reddy

6

1 reference

10 September 2017

Richard R Furman

10

1 reference

10 September 2017

Carol Moreno

15

1 reference

10 September 2017

John M Pagel

16

1 reference

10 September 2017

Samuel Suzuki

18

1 reference

10 September 2017

George Cole

20

1 reference

10 September 2017

language of work or name

English

0 references

publication date

3 April 2017

1 reference

10 September 2017

1 reference

10 September 2017

129

1 reference

10 September 2017

19

1 reference

10 September 2017

2612-2615

1 reference

Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistance

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

New strategies in controlling drug resistance

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437732

10.1182/BLOOD-2016-12-737346

2 December 2018

Identifiers

DOI

1 reference

10.1182/BLOOD-2016-12-737346

10 September 2017

0 references

Dimensions Publication ID

0 references

1 reference

10 September 2017

PubMed publication ID

28373262

1 reference